FDA steps up restrictions on prescribing opioids

19 September 2018
gottlieb_fda_big-1

The US Food and Drug Administration (FDA) has underlined that it is serious about ensuring appropriate and rational prescribing of opioids to counteract their misuse, as the agency approved new safety measures governing their use.

In approving the final Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS), the FDA hopes to help better communicate the risks about the use of these medications to patients and health care professionals.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Company Spotlight



More Features in Pharmaceutical